Filovirus vaccines

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 701-711

  Bradfute, Steven B ^a   Dye, John M ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Ebola; Ebola virus; Ebolavirus; Filovirid; Filoviridae; Filovirus; Marburg virus; Marburgvirus; Mononegavirad; Mononegavirales; Mononegavirus; Vaccine

Indexed keywords

DNA VACCINE; FILOVIRUS VACCINE; GLYCOPROTEIN; LIVE VACCINE; NUCLEOPROTEIN; PARAINFLUENZA VACCINE; PROTEIN VP30; PROTEIN VP35; PROTEIN VP40; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; BUNDIBUGYO VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EBOLA VIRUS; FEVER; FILOVIRUS; FILOVIRUS INFECTION; HEADACHE; HUMAN; INFECTION PREVENTION; MYALGIA; NONHUMAN; POST EXPOSURE PROPHYLAXIS; REPLICON; REVIEW; SINGLE DRUG DOSE; SUDAN VIRUS; VACCINATION; VIRUS GENE; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENETIC VECTORS; HUMANS; VACCINATION; VACCINES, DNA; VIRAL VACCINES; VIRION;

EID: 79959345325     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.15398     Document Type: Review

References (96)

1. Kuhn JH. Filoviruses. A compendium of 40 years of epidemiological, clinical and laboratory studies. Arch Virol 2008; 20:13-360.
2. Warfield KL, Deal EM, Bavari S. Filovirus infections. J Am Vet Med Assoc 2009; 234:1130-9.
3. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses and virus abbreviations. Arch Virol 2010; 155:2083-103.
4. Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346:1669-71. (Pubitemid 26003325)
5. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995; 76:227-36.
6. Dalgard DW, Hardy RJ, Pearson SL, Pucak GJ, Quander RV, Zack PM, et al. Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys. Lab Anim Sci 1992; 42:152-7.
7. 2004. Category A agents. In Centers for Disease Control and Prevention; http://www.bt.cdc.gov/Agent/agentlist.asp.
8. Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, Grard G, et al. Marburg virus infection detected in a common African bat. PLoS One 2007; 2:764.
9. Pourrut X, Souris M, Towner JS, Rollin PE, Nichol ST, Gonzalez JP, Leroy E. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 2009; 9:159.
10. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, Formenty P. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo 2007. Vector Borne Zoonotic Dis 2009; 9:723-8.
11. Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis 2007; 196:176-83.
12. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, et al. McIntosh. Discovery of swine as a host for the Reston ebolavirus. Science 2009; 325:204-6.
13. Riabchikova EI, Kolesnikova LV, Rassadkin Iu N. [Microscopic study of species specific features of hemostatic impairment in Ebola virus infected monkeys]. Vestn Ross Akad Med Nauk 1998; 51-5.
14. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978; 125:131-8. (Pubitemid 8400311)
15. Bowen ET, Platt GS, Simpson DI, McArdell LB, Raymond RT. Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg 1978; 72:188-91. (Pubitemid 8324309)
16. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179:199-202.
17. Siegert R, Shu HL, Slenczka HL, Peters D, Muller G. The aetiology of an unknown human infection transmitted by monkeys (preliminary communication). Ger Med Mon 1968; 13:1-2.
18. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61. (Pubitemid 28397211)
19. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179:203-17.
20. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997; 239:206-16. (Pubitemid 28027084)
21. Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83:6404-15.
22. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100:15889-94. (Pubitemid 38021085)
23. Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007; 196:421-9.
24. + T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91.
25. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004; 200:169-79. (Pubitemid 38982176)
26. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196:404-12.
27. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP. [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. Vopr Virusol 1994; 39:82-4.
28. Chupurnov AA, Chernukhin IV, Ternovoi VA, Kudoiarova NM, Makhova NM, Azaev M, Smolina MP. [Attempts to develop a vaccine against Ebola fever]. Vopr Virusol 1995; 40:257-60.
29. Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol 1996; 44:111-8. (Pubitemid 26056569)
30. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997; 239:389-401. (Pubitemid 28105644)
31. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37. (Pubitemid 28527716)
32. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35 and VP40 proteins. Virology 2001; 286:384-90. (Pubitemid 32721814)
33. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001; 75:2660-4. (Pubitemid 32185029)
34. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, et al.. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005; 79:14189-96. (Pubitemid 41552717)
35. Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 2001; 20:586-93. (Pubitemid 32973804)
36. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19:142-53. (Pubitemid 30618964)
37. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001; 75:11677-85. (Pubitemid 33063259)
38. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
39. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
40. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:177.
41. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6:886-9. (Pubitemid 30644746)
42. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7. (Pubitemid 351967082)
43. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17:572-81.
44. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7. (Pubitemid 38380817)
45. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346:394-401. (Pubitemid 43357883)
46. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:3548.
47. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 2007; 196:413-20.
48. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4:5308.
49. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 2010; 84:10386-94.
50. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80.
51. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:1000212.
52. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010; 6:1000904.
53. Yu JS, Liao HX, Gerdon AE, Huffman B, Scearce RM, McAdams M, et al. Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods 2006; 137:219-28. (Pubitemid 44397161)
54. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77. (Pubitemid 46768881)
55. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13.
56. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400.
57. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
58. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
59. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008; 26:6894-900.
60. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009; 83:7296-304.
61. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009; 4:5547.
62. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in nonhuman primates: an efficacy assessment. Lancet 2006; 367:1399-404.
63. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119-22.
64. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:2.
65. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8. (Pubitemid 351705275)
66. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:1000225.
67. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 2009; 338:1223.
68. th International Symposium on Filoviruses. Tokyo, Japan 2010.
69. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006; 80:2267-79. (Pubitemid 43271533)
70. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
71. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009; 383:348-61.
72. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602. (Pubitemid 34461504)
73. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42. (Pubitemid 40462443)
74. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196:430-7.
75. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502. (Pubitemid 39078769)
76. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417-29. (Pubitemid 351656813)
77. Fuller CL, Ruthel G, Warfield KL, Swenson DL, Bosio CM, Aman MJ, Bavari S. NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol 2007; 9:962-76. (Pubitemid 46394907)
78. Bosio CM, Moore BD, Warfield KL, Ruthel G, Mohamadzadeh M, Aman MJ, Bavari S. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326:280-7. (Pubitemid 39078259)
79. Pattyn S, van der Groen G, Courteille G, Jacob W, Piot P. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet 1977; 1:573-4. (Pubitemid 8048855)
80. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J Clin Microbiol 1981; 13:791-3. (Pubitemid 11047571)
81. van der Groen G, Jacob W, Pattyn SR. Ebola virus virulence for newborn mice. J Med Virol 1979; 4:239-40. (Pubitemid 10206694)
82. Bowen ET, Lloyd G, Harris WJ, Platt GS, Baskerville A, Vella EE. Viral haemorrhagic fever in Southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1977; 1:571-3.
83. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365-73. (Pubitemid 32519767)
84. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, Ruo SL, et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 1992; 166:753-63.
85. Bowen ET, Platt GS, Lloyd G, Raymond RT, Simpson DI. A comparative study of strains of Ebola virus isolated from Southern Sudan and northern Zaire in 1976. J Med Virol 1980; 6:129-38. (Pubitemid 11188426)
86. 1978. Ebola haemorrhagic fever in Sudan. Report of a WHO/International Study Team. Bull World Health Organ 1976; 56:247-70.
87. Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999; 179:192-8.
88. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, Hall WC, Peters CJ. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990; 335:502-5. (Pubitemid 20073056)
89. Hofmann H, Kunz C. [A strain of "Marburg virus" (Rhabdovirus simiae) pathogenic to mice]. Arch Gesamte Virusforsch 1970; 32:244-8.
90. Warfield KL, Alves DA, Bradfute SB, Reed DK, Vantongeren S, Kalina WV, et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J 2007; 4:108.
91. Simpson DI. Marburg agent disease: in monkeys. Trans R Soc Trop Med Hyg 1969; 63:303-9.
92. Johnson ED, Johnson BK, Silverstein D, Tukei P, Geisbert TW, Sanchez AN, Jahrling PB. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol 1996; 11:101-14.
93. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66. (Pubitemid 44435640)
94. Wang D, Hevey M, Juompan LY, Trubey CM, Raja NU, Deitz SB, et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 2006; 353:324-32. (Pubitemid 44397132)
95. Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006; 80:2738-46. (Pubitemid 43346369)
96. Warfield KL, Swenson DL, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 2005; 4:429-40. (Pubitemid 40978702)